9-bromo-2-methyl[1,2,4]triazolo[1,5-c]quinazolin-5(6H)-one | 882517-72-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 9-bromo-2-methyl[1,2,4]triazolo[1,5-c]quinazolin-5(6H)-one
• 英文别名: 9-bromo-2-methyl-6H-[1,2,4]triazolo[1,5-c]quinazolin-5-one；3-bromo-2-methyl-6H-[1,2,4]triazolo[1,5-c]quinazolin-5-one
• CAS: 882517-72-8
• 化学式: C₁₀H₇BrN₄O
• 分子量: 279.096
• InChiKey: XXAHBMLWTZGSMK-UHFFFAOYSA-N

物化性质

• 密度：
  1.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  59.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  9-bromo-2-methyl[1,2,4]triazolo[1,5-c]quinazolin-5(6H)-one 、 9-溴-[1,2,4]噻唑[1,5-c]喹唑啉-5(6H)-酮 生成 4-bromo-2-(5-methyl-2H-[1,2,4]triazol-3-yl)-phenylamine
  参考文献：
  名称：

  Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives

  摘要：

  本发明涉及公式I的卤代咪唑并[1,5-a] [1,2,4]三唑并[1,5-d] [1,4]苯二氮平衍生物，其中R1、R2、R3、R4和n如规范所定义，并且其药学上可接受的酸盐。该化合物可用作认知增强剂或治疗认知障碍、焦虑症、阿尔茨海默病和精神分裂症。

  公开号：

  US20060084801A1
• 作为产物：
  描述：

  2-氨基-5-溴苯甲腈 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 甲苯 为溶剂， 反应 4.0h， 生成 9-bromo-2-methyl[1,2,4]triazolo[1,5-c]quinazolin-5(6H)-one
  参考文献：
  名称：

  Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3)

  摘要：

  DOI：

  10.1021/acs.jmedchem.1c01336

文献信息

• HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE
  申请人：Borchardt Allen J.

  公开号：US20100120741A1

  公开（公告）日：2010-05-13

  The present invention relates to compounds and methods which may be useful as inhibitors of H 1 R and/or H 4 R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

  本发明涉及化合物和方法，这些化合物和方法可能用作H1R和/或H4R的抑制剂，用于治疗或预防炎症性、自身免疫性、过敏性和眼部疾病。
• Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives
  申请人：Knust Henner

  公开号：US20060079507A1

  公开（公告）日：2006-04-13

  The present invention is concerned with a method of treating a disease selected from the group consisting of cognitive disorders, anxiety, Alzheimer's disease, and schizophrenia comprising administering a therapeutically effective amount of a substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives of the following formula wherein R 1 is halogen, lower alkyl, lower alkynyl, cycloalkyl, lower alkoxy, OCF 3 , —NHR, —NHC(O)R or —NHSO 2 R; R 2 is hydrogen, methyl or aryl which is unsubstituted or substituted by one or two substituents selected from the group consisting of halogen and lower alkoxy; R 3 is hydrogen, lower alkyl, lower alkenyl, cycloalkyl, lower alkoxy, —O(CH 2 ) n+1 —O-lower alkyl, —(CH 2 ) n -aryl which is optionally substituted by lower alkyl or halogen, heteroaryl, —NHR, —N(R) 2 , wherein each R can be the same or different, —NHCH 2 C≡CH, or pyrrolidin-1-one; R is hydrogen, lower alkyl, lower alkyl substituted by halogen, heteroaryl, —(CH 2 ) n O-lower alkyl, —NH-lower alkyl, cycloalkyl or aryl, and n is 0, 1, 2 or 3; and with their pharmaceutically acceptable acid addition salts. The invention also provides novel compounds of formula I-A and pharmaceutical compositions containing them. The most preferred indication is Alzheimer's disease.

  本发明涉及一种治疗从认知障碍、焦虑、阿尔茨海默病和精神分裂症中选择的疾病的方法，包括给予下列公式的取代咪唑[1,5-a][1,2,4]三唑[1,5-d][1,4]苯二氮䓬啉衍生物的治疗有效量：其中R1是卤素、较低烷基、较低炔基、环烷基、较低烷氧基、OCF3、—NHR、—NHC(O)R或—NHSO2R；R2是氢、甲基或芳基，未取代或由卤素和较低烷氧基中选择的一种或两种取代基取代；R3是氢、较低烷基、较低烯基、环烷基、较低烷氧基、—O(CH2)n+1—O-较低烷基、—( )n-芳基，可由较低烷基或卤素取代，杂芳基、—NHR、—N(R)2，其中每个R可以相同也可以不同，—NH C≡CH，或吡咯烷酮；R是氢、较低烷基、由卤素取代的较低烷基、杂芳基、—( )nO-较低烷基、—NH-较低烷基、环烷基或芳基，n为0、1、2或3；以及其药学上可接受的酸盐。该发明还提供了公式I-A的新化合物和含有它们的药物组合物。最受欢迎的适应症是阿尔茨海默病。
• SUBSTITUTED IMIDAZO[1,5-A][1,2,4]TRIAZOLO[1,5-D][1,4]BENZODIAZEPINE DERIVATIVES
  申请人：Knust Henner

  公开号：US20100075954A1

  公开（公告）日：2010-03-25

  The present invention is concerned with a method of treating Alzheimer's disease by administering a therapeutically effective amount of a substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine of formula I wherein R 1 , R 2 , and R 3 are as defined herein, and their pharmaceutically acceptable acid addition salts. The invention also provides novel compounds of formula I-A and pharmaceutical compositions containing them.

  本发明涉及通过给予公式I中的取代咪唑[1,5-a] [1,2,4]三唑并[1,5-d] [1,4]苯二氮平的治疗有效量以治疗阿尔茨海默病的方法，其中R1，R2和R3如本文所定义，并且它们的药学上可接受的酸加盐。该发明还提供了公式I-A的新化合物和包含它们的药物组合物。
• Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US08293730B2

  公开（公告）日：2012-10-23

  The present invention is concerned with a method of treating Alzheimer's disease by administering a therapeutically effective amount of a substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine of formula I wherein R1, R2, and R3 are as defined herein, and their pharmaceutically acceptable acid addition salts. The invention also provides novel compounds of formula I-A and pharmaceutical compositions containing them.

  本发明涉及一种通过给予公式I中的取代咪唑[1,5-a][1,2,4]三唑并[1,5-d][1,4]苯二氮平的治疗有效量来治疗阿尔茨海默病的方法，其中R1，R2和R3如本文所定义，并且它们的药学上可接受的酸加盐。本发明还提供了公式I-A的新化合物和含有它们的药物组合物。
• Substituted imidazo [1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US07671048B2

  公开（公告）日：2010-03-02

  The present invention is concerned with a method of treating a disease selected from the group consisting of cognitive disorders, anxiety, Alzheimer's disease, and schizophrenia comprising administering a therapeutically effective amount of a substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives of the following formula wherein R1 is halogen, lower alkyl, lower alkynyl, cycloalkyl, lower alkoxy, OCF3, —NHR, —NHC(O)R or —NHSO2R; R2 is hydrogen, methyl or aryl which is unsubstituted or substituted by one or two substituents selected from the group consisting of halogen and lower alkoxy; R3 is hydrogen, lower alkyl, lower alkenyl, cycloalkyl, lower alkoxy, —O(CH2)n+1—O-lower alkyl, —(CH2)n-aryl which is optionally substituted by lower alkyl or halogen, heteroaryl, —NHR, —N(R)2, wherein each R can be the same or different, —NHCH2C≡CH, or pyrrolidin-1-one; R is hydrogen, lower alkyl, lower alkyl substituted by halogen, heteroaryl, —(CH2)nO-lower alkyl, —NH-lower alkyl, cycloalkyl or aryl, and n is 0, 1, 2 or 3; and with their pharmaceutically acceptable acid addition salts. The invention also provides novel compounds of formula I-A and pharmaceutical compositions containing them. The most preferred indication is Alzheimer's disease.

  本发明涉及一种治疗认知障碍、焦虑、阿尔茨海默病和精神分裂症等疾病的方法，包括给予以下公式的取代咪唑[1,5-a][1,2,4]三唑并[1,5-d][1,4]苯二氮平衍生物的治疗有效量，其中R1是卤素、较低烷基、较低炔基、环烷基、较低烷氧基、OCF3、—NHR、—NHC(O)R或—NHSO2R;R2是氢、甲基或芳基，未经取代或经过一种或两种卤素和较低烷氧基的取代;R3是氢、较低烷基、较低烯基、环烷基、较低烷氧基、—O(CH2)n+1—O-较低烷基、—( )n-芳基，其可选择由较低烷基或卤素取代，杂环芳基、—NHR、—N(R)2，其中每个R可以相同或不同，—NH C≡CH或吡咯烷-1-酮;R为氢、较低烷基、经卤素取代的较低烷基、杂环芳基、—( )nO-较低烷基、—NH-较低烷基、环烷基或芳基，n为0、1、2或3;以及其药学上可接受的酸盐。本发明还提供了公式I-A的新化合物和含有它们的制药组合物。最优选的适应症是阿尔茨海默病。